Tinea Pedis Articles & Analysis: Older
3 news found
Blueberry Therapeutics will use the Series B extension proceeds to continue its development programme for BB2603 for the treatment of onychomycosis, and additional funding will be used to advance other programmes, including in tinea pedis, where there are encouraging efficacy and safety data, and a potentially efficient route to market. ...
BOSTON, Jan. 8, 2021 /PRNewswire-PRWeb/ -- DermBiont, a clinical-stage biotechnology company developing targeted topical therapeutics, announced today that its phase 2b clinical trial with its investigational drug product, DBI-001, for the treatment of tinea pedis resulted in statistically significant decreases in the abundance in T. rubrum, ...
In addition to the company’s lead product (DBI-001) in development to treat atopic dermatitis, onychomycosis, and tinea pedis, the company is advancing four other topical clinical assets across a wide range of skin diseases, including seborrheic dermatitis (DBI-002) and seborrheic keratosis (SM-020). ...